Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Ovid Therapeutics (OVID) over the last 4 years, with Q3 2025 value amounting to $365000.0.

  • Ovid Therapeutics' Non Operating Income rose 14679.49% to $365000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 8768.45%. This contributed to the annual value of $35.5 million for FY2024, which is 41061.5% up from last year.
  • Ovid Therapeutics' Non Operating Income amounted to $365000.0 in Q3 2025, which was up 14679.49% from $389000.0 recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Non Operating Income ranged from a high of $29.0 million in Q2 2024 and a low of -$780000.0 during Q3 2024
  • Its 4-year average for Non Operating Income is $3.1 million, with a median of $836085.0 in 2022.
  • Data for Ovid Therapeutics' Non Operating Income shows a peak YoY increase of 154614.51% (in 2024) and a maximum YoY decrease of 20051.55% (in 2024) over the last 5 years.
  • Quarter analysis of 4 years shows Ovid Therapeutics' Non Operating Income stood at $668123.0 in 2022, then soared by 329.11% to $2.9 million in 2023, then plummeted by 48.76% to $1.5 million in 2024, then tumbled by 75.15% to $365000.0 in 2025.
  • Its Non Operating Income stands at $365000.0 for Q3 2025, versus $389000.0 for Q2 2025 and $2.3 million for Q1 2025.